[22 May 2013]
Products Affected - Description
Reason for the Shortage
- APP states the reason for the shortage was increased demand.
Meropenem Injection, APP
500 mg vial, 10 count (NDC 63323-0507-20)
1 gram vial, 10 count (NDC 63323-0508-30)
500 mg Novaplus vial, 1 count (NDC 63323-0507-21)
1 gram Novaplus vial, 1 count (NDC 63323-0508-31)
Meropenem Injection, Hospira
500 mg vial, 25 count (NDC 00409-3505-01)
1 gram vial, 25 count (NDC 00409-3506-01)
Merrem Injection, AstraZeneca
500 mg vial, 10 count (NDC 00310-0325-20)
1 gram vial, 10 count (NDC 00310-0321-30)
Meropenem Injection, Sandoz
500 mg vial, 10 count (NDC 00781-3265-95)
1 gram vial, 10 count (NDC 00781-3267-95)
Estimated Resupply Dates
- All presentations are available.
May 22, 2013; April 24, 2013; April 23, 2013; March 15, 2013; February 20, 2013; February 6, 2013; January 24, 2013; January 10, 2013; January 7, 2013; December 14, 2012; November 30, 2012; November 27, 2012; October 24, 2012, University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins